Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study of Biomarker Profiles in Asia Pacific erb2+/HER2 Breast Cancer Patients Treated With Lapatinib (BioPATH)

This study has been completed.
Information provided by (Responsible Party):
GlaxoSmithKline Identifier:
First received: November 24, 2010
Last updated: April 23, 2015
Last verified: March 2015
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: September 2014
  Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)